<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112619</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430504</org_study_id>
    <secondary_id>U01CA081457</secondary_id>
    <secondary_id>PBTC-019</secondary_id>
    <nct_id>NCT00112619</nct_id>
  </id_info>
  <brief_title>Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors</brief_title>
  <official_title>A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of&#xD;
      topotecan when given by intraventricular infusion in treating young patients with neoplastic&#xD;
      meningitis due to leukemia, lymphoma, or solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of intraventricular topotecan in young&#xD;
           patients with neoplastic meningitis secondary to leukemia, lymphoma, or solid tumors.&#xD;
&#xD;
        -  Determine the toxic effects and dose-limiting toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine whether the MTD of this drug is also the pharmacokinetic optimal dose, defined&#xD;
           by the topotecan lactone concentration in the cerebral spinal fluid (CSF), in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in the CSF of these patients.&#xD;
&#xD;
        -  Correlate observed effects of post-treatment central review imaging (if feasible) with&#xD;
           response to this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, dose-escalation, multicenter study.&#xD;
&#xD;
        -  Induction therapy (weeks 1-4): Patients receive topotecan intraventricularly* over 5&#xD;
           minutes on days 1-5 in weeks 1 and 3. Patients then proceed to consolidation therapy in&#xD;
           week 5.&#xD;
&#xD;
      NOTE: *Patients who are willing, receive 1 intralumbar (instead of intraventricular) dose of&#xD;
      topotecan on day 1 of week 3 only.&#xD;
&#xD;
        -  Consolidation therapy (weeks 5-10): Patients receive topotecan intraventricularly on&#xD;
           days 1-5 in weeks 5 and 8. Patients then proceed to maintenance therapy in week 11.&#xD;
&#xD;
        -  Maintenance therapy (weeks 11-54): Patients receive topotecan intraventricularly on days&#xD;
           1-5 in weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of intraventricular topotecan until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Once the MTD is determined, the cohort is expanded to 25 patients and the MTD is declared the&#xD;
      pharmacokinetic optimal dose provided 23 of 25 patients treated at the MTD achieve the target&#xD;
      pharmacokinetic parameter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28-49 patients will be accrued for this study within 9-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual and company withdrawing support to supply the drug&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum tolerated dose of intraventricular topotecan on this schedule</measure>
    <time_frame>First 14 days of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with dose-limiting toxicity</measure>
    <time_frame>First 14 days of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the dose of intraventricular topotecan that will result in cerebrospinal fluid lactone concentrations exceeding 1 ng/mL for at least 8 hours after an intrathecal injection</measure>
    <time_frame>Day 1 of Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with objective documentation of tumor response to intraventricular topotecan</measure>
    <time_frame>Weeks 5, 11 and then every 12 weeks until off study</time_frame>
    <description>MRI of the brain and spine is obtained pre-consolidation, pre-maintenance, and then every 12 weeks in maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 1 of Week 1</time_frame>
    <description>The cerebrospinal fluid (CSF) concentration-time profile for topotecan after intrathecal CSF administration will be modeled from the CSF samples collected on day 1 of week 1. Individual pharmacokinetic parameters estimated will include volume of central compartment, elimination rate constant, half-life, and clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of imaging parameters with tumor response</measure>
    <time_frame>Pre-treatment, week 5, week 11, and then every 12 weeks until off study</time_frame>
    <description>MRI scans of the brain and spine is obtained pre-treament, pre-consolidation, pre-maintenance, and then every 12 weeks on maintenance.</description>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Carcinoma of Unknown Primary</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).</description>
    <other_name>Hycamptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neoplastic meningitis secondary to leukemia, lymphoma (including&#xD;
             AIDS-related lymphoma), or solid tumor (including primary CNS tumors or carcinomas of&#xD;
             unknown primary site), defined by 1 of the following criteria:&#xD;
&#xD;
               -  Cerebral spinal fluid (CSF) cell count &gt; 5/μL AND evidence of blast cells on&#xD;
                  cytospin or by cytology (for patients with leukemia or lymphoma)&#xD;
&#xD;
               -  Presence of tumor cells on cytospin or cytology OR unequivocal presence of&#xD;
                  meningeal disease by MRI (for patients with solid tumor)&#xD;
&#xD;
          -  No conventional therapy for neoplastic meningitis exists&#xD;
&#xD;
               -  Patients with CNS leukemia or lymphoma must be refractory to conventional&#xD;
                  therapy, including radiotherapy (i.e., second or greater relapse)&#xD;
&#xD;
          -  Patients with CNS leukemia or lymphoma must have had a negative bone marrow aspiration&#xD;
             within the past 2 weeks&#xD;
&#xD;
          -  No clinical evidence of obstructive hydrocephalus&#xD;
&#xD;
          -  No compartmentalization of CSF flow by radioisotope indium In 111 or technetium Tc 99&#xD;
             DTPA flow study&#xD;
&#xD;
          -  No ventriculoperitoneal or ventriculoatrial shunt unless patient is completely&#xD;
             shunt-independent&#xD;
&#xD;
          -  No impending spinal cord compression or other CNS involvement (e.g., acute visual loss&#xD;
             secondary to optic nerve involvement) requiring emergent local radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Lansky 60-100% (≤ 16 years of age) OR&#xD;
&#xD;
          -  Karnofsky 60-100% (&gt; 16 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Calcium ≥ 7 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Sodium 125-150 mmol/L&#xD;
&#xD;
          -  Magnesium ≥ 0.7 mmol/L&#xD;
&#xD;
          -  Must have or be willing to have an intraventricular access device (i.e., Ommaya&#xD;
             reservoir)&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
               -  HIV-positive patients with AIDS-related lymphomatous meningitis are eligible&#xD;
&#xD;
          -  No other significant uncontrolled systemic medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior biologic therapy or immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior intra-colony stimulating factory (CSF) chemotherapy (2&#xD;
             weeks for liposomal cytarabine)&#xD;
&#xD;
          -  At least 3 weeks since prior systemic chemotherapy for leptomeningeal disease&#xD;
&#xD;
          -  Concurrent systemic chemotherapy to control systemic disease or bulk CNS disease&#xD;
             allowed provided the systemic chemotherapy is not an investigational agent OR any of&#xD;
             the following:&#xD;
&#xD;
               -  High-dose (&gt; 1 g/m^2) methotrexate&#xD;
&#xD;
               -  High-dose (&gt; 1 g/m^2) cytarabine&#xD;
&#xD;
               -  Fluorouracil&#xD;
&#xD;
               -  Capecitabine&#xD;
&#xD;
               -  Thiotepa&#xD;
&#xD;
               -  Nitrosoureas&#xD;
&#xD;
               -  Topotecan&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 8 weeks since prior craniospinal radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent CNS radiotherapy&#xD;
&#xD;
               -  Concurrent radiotherapy to extra-CNS sites (e.g., painful bone metastases not in&#xD;
                  the craniospinal axis) allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent intra-CSF or systemic therapy for leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Blaney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett, Executive Director Operations and Biostatistics Center</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related diffuse small cleaved cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related lymphoblastic lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <keyword>HIV-associated Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>primary central nervous system Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>leptomeningeal metastases</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>meningeal leukemia</keyword>
  <keyword>secondary central nervous system Hodgkin lymphoma</keyword>
  <keyword>secondary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

